Status:
UNKNOWN
Regulation and Mechanism of New Compound Functional Ingredients in Infants
Lead Sponsor:
Peking University Third Hospital
Collaborating Sponsors:
Peking University First Hospital
Peking University People's Hospital
Conditions:
Sialic Acid
Oligosaccharide
Eligibility:
All Genders
Brief Summary
A prospective, multicentre, randomized, double-blind, parallel control study was conducted to analyze the changes in growth, intestinal flora, and immune function of infants with different feeding pat...
Detailed Description
Breast milk is the most beneficial and safe natural food for the growth and development of infants, but some mothers cannot complete breast feeding.For infants who cannot be breastfed, how to improve ...
Eligibility Criteria
Inclusion
- Healthy infants;
- Full-term (gestational age ≥37 weeks);
- Birth weight 2500-4500g;
- Mothers have no history of diabetes, hypertension, heart disease, and other diseases during pregnancy;
- The guardian signed informed consent and voluntarily enrolled into the group and promised to complete systematic follow-up.
Exclusion
- Hospitalization with cognitive impairment or deformity ≥2 days
- History of birth asphyxia (Apgar score \< 3)
- Severe allergy to milk and serious medical conditions such as intracranial hemorrhage, chronic diarrhea, necrotizing colitis, or acute infection
- The guardian refused to enroll or could not complete the system follow-up.
Key Trial Info
Start Date :
April 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT05297006
Start Date
April 1 2022
End Date
December 31 2022
Last Update
March 25 2022
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University People's Hospital
Beijing, Beijing Municipality, China, 100191
2
Peking University Third Hospital
Beijing, Beijing Municipality, China, 100191
3
Peking University First Hospital
Beijing, China, 100191